Latest News on KVUE

Financial News Based On Company


Advertisement
Advertisement

Colgate Has Raised Its Dividend for 63 Years. These 3 Staples Stocks Offer Income

https://247wallst.com/investing/2026/11/19/colgate-has-raised-its-dividend-for-63-years-these-3-staples-stocks-offer-income/
This article examines three consumer staples companies—Colgate-Palmolive, Kimberly-Clark, and Hormel Foods—highlighting their long histories of dividend increases and their current financial health. While Colgate-Palmolive offers the most secure payout with 63 years of increases, Kimberly-Clark's recent Kenvue acquisition adds debt that could limit future raises, and Hormel Foods, despite a high yield, shows tighter dividend coverage. The piece advises investors to match each stock to their income priorities, whether it's reliable raises or higher current yield.

Johnson & Johnson's Strategic Shift: Why Diversification Is Giving Way to Focus

https://www.pharmexec.com/view/pharmaceutical-company-strategy-johnson-johnson-diversification
Johnson & Johnson is strategically shifting away from its long-standing diversification model by separating its consumer health business (Kenvue) and proposing to spin off DePuy Synthes, its orthopedics business. This move aims to concentrate J&J's focus on Innovative Medicine and MedTech, evaluating whether these core segments create more value together than apart. The article emphasizes the importance of applying "capability, capital allocation, and patient-value tests" to justify continued common ownership of remaining businesses and guide future investment decisions.

Martin Cobb’s Past Picks: Kenvue, Starbucks & Canadian National Railway

https://www.bnnbloomberg.ca/video/shows/market-call/2026/11/17/martin-cobbs-past-picks-kenvue-starbucks-canadian-national-railway/
Martin Cobb, senior vice-president in equities at Lorne Steinberg Wealth Management, iA Private Wealth, reviewed his past stock picks: Kenvue, Starbucks, and Canadian National Railway. He discussed their current market performance in this BNN Bloomberg segment.

Kimberly-Clark Corporation (KMB) Latest Stock News & Headlines - Yahoo Finance

https://ca.finance.yahoo.com/quote/KMB/news/
This article provides a compilation of recent news and headlines concerning Kimberly-Clark Corporation (KMB), including analyst expectations, stock fair value assessments, dividend announcements, and updates on its Kenvue acquisition. It also features performance data for KMB against the S&P 500, showing its trailing total returns.

FDA Approval for ROGAINE EXTRA STRENGTH (FOR MEN) issued to KENVUE BRANDS

https://www.quantisnow.com/insight/fda-approval-for-rogaine-extra-strength-for-men-issued-to-6795360
The FDA has approved a labeling supplement (SUPPL-22) for Kenvue's Rogaine Extra Strength (for men) on November 13, 2026. This is a routine regulatory update concerning changes to the package insert and carton labels for an existing over-the-counter product, not a new product or an alteration to its active ingredient, minoxidil 5%. For shareholders, this signifies the product remains approved and marketed under Kenvue's existing NDA.
Advertisement

FDA Approval for WOMEN'S ROGAINE issued to KENVUE BRANDS

https://www.quantisnow.com/insight/fda-approval-for-women39s-rogaine-issued-to-kenvue-brands-6795364
The FDA has approved a labeling supplement (SUPPL-23) for Kenvue Brands' Women's Rogaine minoxidil 5% foam. This approval, dated November 13, 2026, concerns routine package insert and container/carton label changes for the existing over-the-counter product, not a new product or indication. For shareholders, this is considered a standard update with no price-relevant change to the product itself.

JPMorgan resumes Kimberly Clark stock coverage with neutral rating By Investing.com

https://uk.investing.com/news/stock-market-news/jpmorgan-resumes-kimberly-clark-stock-coverage-with-neutral-rating-93CH-4986910
JPMorgan has resumed coverage of Kimberly Clark (NYSE:KMB) with a Neutral rating and a price target of $113.00, noting that the stock is currently trading just below this target. Despite six analysts revising earnings downwards for the upcoming period, the company has consistently raised its dividend for 54 consecutive years, currently yielding 4.6%. The firm's analysis follows Kimberly Clark's strong third-quarter 2026 results and the acquisition of Kenvue, with projected EPS growth for 2027 and 2028.

JPMorgan resumes Kimberly Clark stock coverage with neutral rating By Investing.com

https://in.investing.com/news/stock-market-news/jpmorgan-resumes-kimberly-clark-stock-coverage-with-neutral-rating-93CH-5708937
JPMorgan has resumed coverage on Kimberly Clark (NYSE:KMB) with a Neutral rating and a price target of $113.00, slightly above its current trading price. The firm's analysis, following Kimberly Clark's Q3 2026 results and the KVUE transaction, projects EPS growth for 2027 and 2028 despite recent downward revisions by some analysts. The company continues its streak of dividend increases and focuses on integration post-acquisition.

FDA Approval for MEN'S ROGAINE issued to KENVUE BRANDS

https://www.quantisnow.com/insight/fda-approval-for-men39s-rogaine-issued-to-kenvue-brands-6795363
The FDA has approved supplement SUPPL-23 to Kenvue Brands' New Drug Application 021812 for Men's Rogaine (minoxidil 5%). This approval specifically concerns labeling updates for the package insert and carton labels, not a change to the drug's formula or the approval of a new product. The supplement was approved on November 13, 2026.

FDA Approval for ROGAINE EXTRA STRENGTH (FOR MEN) issued to KENVUE BRANDS

https://quantisnow.com/insight/fda-approval-for-rogaine-extra-strength-for-men-issued-to-6795360
The FDA has approved a labeling supplement (SUPPL-22) for Kenvue's Rogaine Extra Strength (for men) on November 13, 2026. This routine regulatory update covers package insert and carton label changes but does not alter the product's active ingredient or strength, which remains 5% minoxidil. For shareholders, this is considered a standard update for an existing over-the-counter product.
Advertisement

FDA Approval for ROGAINE (FOR MEN) issued to KENVUE BRANDS

https://www.quantisnow.com/insight/fda-approval-for-rogaine-for-men-issued-to-kenvue-brands-6795362
The FDA has approved a labeling supplement (SUPPL-38) for Kenvue Brands' ROGAINE (FOR MEN) on November 13, 2026. This approval pertains to updates for the package insert and container/carton labels under New Drug Application 019501, and does not involve changes to the product itself or its 2% minoxidil solution strength.

FDA Approval for ROGAINE (FOR WOMEN) issued to KENVUE BRANDS

https://www.quantisnow.com/insight/fda-approval-for-rogaine-for-women-issued-to-kenvue-brands-6795361
The FDA has approved a labeling supplement (SUPPL-38) for Kenvue Brands' ROGAINE (FOR WOMEN) minoxidil solution, specifically for package insert and container/carton changes. This routine regulatory update, dated 11/13/2026, does not involve a new drug or new indication, nor does it alter the product's approved uses or 2% minoxidil strength. For shareholders, it signifies that the product remains approved with cleared labeling.

How Many Shares of Kimberly-Clark, Clorox or Procter & Gamble Pay $1,000 a Month in Dividends?

https://www.tikr.com/blog/how-many-shares-of-kimberly-clark-clorox-or-procter-gamble-pay-1000-a-month-in-dividends?ref=yahoofinancedividend&tlnk=yf-261115-p82ch8qc
This article examines how many shares of Kimberly-Clark, Clorox, or Procter & Gamble an investor would need to hold to receive $1,000 per month in dividends. It highlights the cost, yield, and dividend coverage of each stock, noting that Procter & Gamble offers the most expensive but best-covered dividend. The analysis suggests P&G as the most reliable choice for retirees, despite its higher upfront cost.

Better Dividend Stock for Retirees: General Mills vs. Kimberly-Clark

https://www.tikr.com/blog/better-dividend-stock-for-retirees-general-mills-vs-kimberly-clark
This article compares General Mills (GIS) and Kimberly-Clark (KMB) as dividend stocks for retirees, focusing on yield, dividend growth, and payout ratios. While Kimberly-Clark boasts a longer history of consecutive dividend raises and recently acquired Kenvue, General Mills offers a significantly higher current yield of 7.0%. The analysis suggests General Mills is the better choice for current income, despite its dividend likely remaining flat for a few years as it prioritizes debt reduction.

A $1,500,000 Portfolio in Clorox, Kimberly-Clark and PepsiCo Pays $67,627 a Year in Dividends. Here’s What Happens if One Cuts

https://www.tikr.com/blog/a-1500000-portfolio-in-clorox-kimberly-clark-and-pepsico-pays-67128-a-year-in-dividends-heres-what-happens-if-one-cuts
A hypothetical $1.5 million portfolio split across Clorox, Kimberly-Clark, and PepsiCo yields $67,627 annually in dividends. Clorox has the highest payout ratio at 133% of free cash flow, making its dividend the most vulnerable to a cut. If Clorox were to halve its dividend, the portfolio's income would drop to approximately $56,100, while a complete stoppage would reduce it to about $44,500.
Advertisement

Three Megamergers Closed This Year, and $120,000 Across the Combined Companies Pays $5,050 a Year

https://247wallst.com/investing/2026/11/12/three-megamergers-closed-this-year-and-120000-across-the-combined-companies-pays-5050-a-year/
Three significant corporate mergers involving Kimberly-Clark, Public Storage, and Equity Residential/AvalonBay Communities (now Vivmark Residential) have recently concluded. Investing $40,000 in each of these combined entities, totaling $120,000, is projected to generate $5,050 in annual passive income through dividends. While these mergers offer increased scale and potential synergies, Kimberly-Clark's dividend growth streak faces a test due to expected dilutive EPS, and the long-term dividend payouts depend on successful integration and cost savings.

Kimberly-Clark has paid a dividend for 92 consecutive years and raised it annually for 54.

https://www.stocktitan.net/news/KMB/kimberly-clark-declares-quarterly-iugjiafxjxj6.html
Kimberly-Clark (NASDAQ: KMB) has declared a regular quarterly cash dividend of $1.28 per share, payable on January 5, 2027, to stockholders of record on December 4, 2026. The company boasts a long history of dividend payments, having distributed dividends for 92 consecutive years and increased them annually for the past 54 years. Kimberly-Clark is recognized as a Dividend Aristocrat and will hold its next annual shareholder meeting on May 13, 2027.

Is Jim Cramer-backed Cardinal Health’s Dividend Safe?

https://sg.finance.yahoo.com/news/jim-cramer-backed-cardinal-health-160807242.html
This article examines the safety of Cardinal Health's (NYSE:CAH) dividend, which is favored by Jim Cramer and listed among his top dividend stocks. Despite a small recent dividend increase, the company's strong operating cash flow, even after accounting for litigation payments, suggests its dividend is secure. The analysis compares Cardinal Health's dividend sustainability to other consumer and pipeline stocks Cramer has discussed, highlighting cash flow as a key indicator.

Options on 22,218 shares at $120 are among a Kimberly-Clark (KMB) officer's holdings.

https://www.stocktitan.net/sec-filings/KMB/form-3-kimberly-clark-corp-initial-statement-of-beneficial-ownership-7076282ad977.html
Kimberly-Clark's Pres, Enterprise Growth Market, Anindya Dasgupta, reported holdings as of November 2, 2026. These include 2,401 common shares, various restricted share units totaling 31,377 underlying common shares, and options to purchase 22,218 shares at an exercise price of $120, expiring July 31, 2035. These securities were primarily received in connection with Kimberly-Clark's acquisition of Kenvue.

Kimberly-Clark's Dividend Is Up 392% Since 1999. Can Its $49 Billion Deal Put That at Risk?

https://247wallst.com/investing/2026/11/08/kimberly-clarks-dividend-is-up-392-since-1999-can-its-49-billion-deal-put-that-at-risk/
Kimberly-Clark (KMB) has consistently raised its dividend for 54 consecutive years, increasing its quarterly payout from $0.26 in 1999 to $1.28 despite stagnant revenue. However, the company's free cash flow in 2025 barely covered its dividend payments, and a recent $49 billion acquisition of Kenvue, funded partly by debt, introduces potential earnings dilution. Income investors are closely watching for signs of whether the dividend streak can continue amidst these financial pressures and integration challenges.
Advertisement

Kimberly-Clark Beats Q3 Estimates as China Diaper Controversy Cuts Into Huggies Sales

https://finance.biggo.com/news/4faa8579-bf92-42ab-bbd9-f95dd0348cb7
Kimberly-Clark reported Q3 2026 adjusted earnings of $1.70 per share, exceeding the $1.64 consensus, with revenue of $4.134 billion slightly surpassing estimates. However, organic sales fell 1.3%, primarily due to a social media-driven controversy in China's diaper market affecting Huggies sales, even though authorities found no evidence against the product's safety. The company reaffirmed its 2026 outlook and expects $1.9 billion in cost synergies over three years from its Kenvue acquisition.

Kimberly-Clark Third Quarter 2026 Financial Results Available on Company's Investor Relations Website

https://www.stocktitan.net/news/KMB/kimberly-clark-third-quarter-2026-financial-results-available-on-h23dhotrbgy6.html
Kimberly-Clark reported Q3 2026 net sales of $4.1 billion, a 0.4% decrease, with adjusted continuing-operations EPS rising 17.2% to $1.70, despite a decline in organic sales. The company reaffirmed its 2026 standalone outlook, projecting mid-single-digit adjusted operating profit growth and high-single-digit adjusted EPS growth from continuing operations on a constant-currency basis. The results were impacted by the recent Kenvue acquisition and a social media disruption in China affecting International Personal Care sales.

Kimberly-Clark Corporation Announces Expiration and Final Results of Exchange Offers for Kenvue Notes

https://www.prnewswire.com/news-releases/kimberly-clark-corporation-announces-expiration-and-final-results-of-exchange-offers-for-kenvue-notes-302927190.html
Kimberly-Clark Corporation announced the final results of its exchange offers for Kenvue Notes, which expired on November 2, 2026. The company sought to exchange Kenvue Notes for up to $7 billion in new Kimberly-Clark Notes and cash, along with soliciting consents to amend the Kenvue Indenture. A significant percentage of outstanding Kenvue Notes were tendered across all series, and the settlement of the exchange offers is expected on November 4, 2026.

Kimberly-Clark 3Q 2026: Revenue $4.13B, EPS $5.37 — 10-Q Summary

https://www.tradingview.com/news/tradingview:fa45e25d34f86:0-kimberly-clark-3q-2026-revenue-4-13b-eps-5-37-10-q-summary/
Kimberly-Clark reported relatively flat net sales year over year in the third quarter of 2026, with favorable currency and Arbex Joint Venture sales offset by lower organic sales. Net income significantly increased by 302% to $1.79 billion, largely due to a $1.4 billion after-tax gain from the IFP transaction. Diluted EPS rose to $5.37 from $1.34 in the prior year quarter.

Huggies Maker Kimberly-Clark Says China Diaper Allegations Were Unfounded, but Sales Damage Lingers

https://www.benzinga.com/markets/earnings/26/11/62931180/huggies-maker-kimberly-clark-says-china-diaper-allegations-were-unfounded-but-sales-damage-lingers
Kimberly-Clark Corp. reported better-than-expected third-quarter 2026 results despite facing challenges like rising costs, market uncertainty, and lingering sales damage from unsubstantiated diaper allegations in China. The company reaffirmed its full-year outlook, supported by strong performance in North American tissue and personal care businesses, and completed the acquisition of Kenvue. Management indicated that rebuilding consumer trust in China would take time, and a North American product launch was postponed to 2027.
Advertisement

Kimberly-Clark Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/62919740/kimberly-clark-q3-2026-earnings-call-transcript
Kimberly-Clark completed its acquisition of Kenvue, marking a significant milestone in its transformation strategy, with plans to enhance capabilities in consumer goods and healthcare. The company reported solid Q3 results, noting strong performance in North America, particularly in tissue and personal care, despite some headwinds like cost pressures and a social media crisis in China. Strategic initiatives include a focus on seamless integration with a three-phase plan (Ready, Set, Grow) and leveraging synergies, with a target of $1.9 billion in cost synergies, focusing on overhead, COGS, and sales/marketing efficiencies.

Kimberly-Clark Q3 2026: Six Straight Beats, Now Carrying Kenvue's Debt

https://247wallst.com/cards/kimberly-clark-q3-2026-earnings-kmb-01m6nr124wn6fbqaryc7cy9h48
Kimberly-Clark reported a strong third quarter in 2026, beating EPS and revenue estimates for the sixth consecutive time. However, the company is now facing a substantial increase in debt due to the recent $49 billion acquisition of Kenvue. Despite a decline in organic sales, management reaffirmed its standalone outlook for 2026, focusing on debt management and integrating the new consumer health business.

A director's 9,596 stock units cannot be sold until he leaves the board of Kimberly-Clark (KMB).

https://www.stocktitan.net/sec-filings/KMB/form-3-kimberly-clark-corp-initial-statement-of-beneficial-ownership-4e2a40dc248d.html
Kimberly-Clark Corporation director Richard E. Allison Jr. reported direct holdings of 3,743 common shares and 9,596 restricted share units. These units are payable one-for-one in common stock but cannot be sold or transferred until Allison's service on the board ends. Both the common shares and restricted units were acquired in connection with Kimberly-Clark's acquisition of Kenvue.

Kimberly-Clark (KMB): SEC Form 3 filed by new insider Merlo Larry J

https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-merlo-larry-j-6772089
A new SEC Form 3 filing reveals that Kimberly-Clark (KMB) insider Larry Merlo has 10,504 restricted share units. These units were received from Kenvue deferred units and are payable on a 1-for-1 basis. The alert was delivered by Quantisnow, highlighting a neutral AI summary for the filing.

Estée Lauder Companies outlines 2030 growth plans in ‘next chapter’ after Beauty Reimagined turnaround

https://cosmeticsbusiness.com/est%C3%A9e-lauder-companies-outlines-2030-growth-plans
Estée Lauder Companies (ELC) has announced its "next chapter" growth plans, aiming for mid-single-digit organic sales growth and double-digit adjusted EPS growth annually through fiscal 2030. This strategy follows the successful "Beauty Reimagined" turnaround, which saw the company return to growth in fiscal year 2026. ELC plans to expand consumer reach, innovate, and amplify brand desirability, while operating under a new "One ELC" global business model.
Advertisement

Bear of the Day: KimberlyClark (KMB)

https://finviz.com/news/415112/bear-of-the-day-kimberlyclark-kmb
Kimberly-Clark (KMB) has been designated "Bear of the Day" due to disappointing growth, stagnant sales, and new financial challenges arising from its Kenvue acquisition. The company's stock has underperformed the S&P 500, and analysts have been cutting earnings forecasts, leading to a Zacks Rank #5 (Strong Sell). While the Kenvue acquisition offers potential, the immediate outlook remains uncertain, suggesting investors might find better opportunities elsewhere in the consumer staples sector.

427,308 Shares in Kimberly-Clark Corporation $KMB Purchased by Associated Banc Corp

https://www.marketbeat.com/instant-alerts/filing-427308-shares-in-kimberly-clark-corporation-kmb-purchased-by-associated-banc-corp-2026-11-04/
Associated Banc Corp has acquired a new position in Kimberly-Clark Corporation (NASDAQ:KMB), purchasing 427,308 shares valued at approximately $41.63 million in the third quarter. This makes Kimberly-Clark the 23rd largest holding in Associated Banc Corp's portfolio. Other institutional investors have also adjusted their stakes in the company, with several increasing their holdings.

Kenvue deal brings Kimberly Clark (KMB) CEO Michael D. Hsu 10 shares.

https://www.stocktitan.net/sec-filings/KMB/form-4-kimberly-clark-corp-insider-trading-activity-ba6c7da02c9b.html
Kimberly Clark Corp's Chairman and CEO, Michael D. Hsu, acquired 10 shares of common stock on November 2, 2026. These shares were received in respect of Kenvue Inc. common stock held when Kimberly Clark acquired Kenvue. Following this transaction, Hsu's direct holdings increased to 332,826 shares, and he also holds 21,991 shares indirectly through a trust.

Can Kimberly-Clark's Kenvue Acquisition Unlock Long-Term Growth?

https://www.tradingview.com/news/zacks:077732536094b:0-can-kimberly-clark-s-kenvue-acquisition-unlock-long-term-growth/
Kimberly-Clark has acquired Kenvue, significantly expanding its product portfolio and global reach with 10 billion-dollar brands across personal care and healthcare categories. The acquisition is expected to generate $2.1 billion in run-rate synergies, including cost savings and incremental profit. Kimberly-Clark aims to strengthen its market position and capitalize on the growing health and wellness market through this strategic move.

Kimberly-Clark Corporation Announces Expiration and Final Results of Exchange Offers for Kenvue Notes

https://www.stocktitan.net/news/KMB/kimberly-clark-corporation-announces-expiration-and-final-results-of-0j5siyeijenk.html
Kimberly-Clark (NASDAQ: KMB) has announced the final results of its exchange offers for Kenvue notes, with the offers expiring on November 2, 2026. The company successfully obtained the required consents to amend Kenvue’s debt agreement, with participation rates ranging from 73.93% for 2028 notes to 98.54% for 2053 notes. Settlement is anticipated on November 4, 2026, when the amendments to the debt agreement will become operative.
Advertisement

Kenvue Is Leaving the S&P 500: Here’s What It Means for Investors

https://247wallst.com/investing/2026/11/02/kenvue-is-leaving-the-sp-500-heres-what-it-means-for-investors/
Kenvue is being replaced by Okta in the S&P 500 on November 4, 2026, due to its acquisition by Kimberly-Clark. Kenvue shareholders will receive $3.50 cash plus 0.14625 Kimberly-Clark shares per Kenvue share, and their dividend income will shift from Kenvue's $0.21 to Kimberly-Clark's $1.28 quarterly payout. Investors should monitor Kimberly-Clark's stock price and post-closing dividend announcements, as the deal's value changes with Kimberly-Clark's share price and a potential dividend cut would impact income investors.

10,003 Kimberly-Clark Corporation $KMB Shares Acquired by GRIMES & Co WEALTH MANAGEMENT LLC

https://www.marketbeat.com/instant-alerts/filing-10003-kimberly-clark-corporation-kmb-shares-acquired-by-grimes-co-wealth-management-llc-2026-11-03/
GRIMES & Co WEALTH MANAGEMENT LLC increased its stake in Kimberly-Clark Corporation by 7.1% in the third quarter, acquiring an additional 10,003 shares, bringing their total holdings to 150,072 shares valued at $14.62 million. This comes amidst other institutional investors also acquiring significant positions in the company. Kimberly-Clark recently completed the acquisition of Kenvue, adding brands like Tylenol and aiming for $2.1 billion in synergies, though analysts express concerns about integration risks and potential near-term financial pressures.

Kimberly-Clark completes acquisition of Kenvue

https://www.pulpapernews.com/20261103/18345/kimberly-clark-completes-acquisition-kenvue
Kimberly-Clark Corporation has announced the completion of its acquisition of Kenvue, creating a global leader in consumer health and wellness. This merger brings together leading portfolios, including 10 billion-dollar brands such as Huggies, Listerine, and Kleenex, aiming to provide extraordinary care for billions worldwide. Mike Hsu, Chairman and CEO of Kimberly-Clark, emphasized the company's commitment to speed and purpose to unlock the full potential of this combination for consumers, customers, and shareholders.

Form POS AM Kenvue Inc.

https://www.streetinsider.com/SEC+Filings/Form+POS+AM+Kenvue+Inc./27275196.html
Kenvue LLC, as successor to Kenvue Inc., filed a Post-Effective Amendment to its Registration Statement on Form S-4. This amendment deregisters previously registered debt securities following Kimberly-Clark Corporation's acquisition of Kenvue. The acquisition was completed on November 2, 2026, through a merger agreement.

Form POSASR Kenvue Inc.

https://www.streetinsider.com/SEC+Filings/Form+POSASR+Kenvue+Inc./27275194.html
Kenvue LLC, as successor in interest to Kenvue Inc., has filed a Post-Effective Amendment to its Form S-3 Registration Statement. This amendment deregisters previously registered securities of Kenvue Inc. following its acquisition by Kimberly-Clark Corporation on November 2, 2026. The acquisition involved a two-step merger, with Kenvue LLC surviving as a direct wholly-owned subsidiary of Kimberly-Clark.
Advertisement

Kimberly-Clark Completes $49 Billion Kenvue Acquisition, Tylenol Brand Officially Joins Portfolio

https://finance.biggo.com/news/5ef27cb9-3ae0-4db0-b765-6f8fde0472cc
Kimberly-Clark has finalized its $49 billion acquisition of Kenvue, adding major brands like Tylenol, Neutrogena, and Listerine to its portfolio. The combined entity, now a global leader in personal care and consumer health, anticipates achieving $2.1 billion in run-rate synergies, including $1.9 billion in cost reductions over three years. CEO Mike Hsu plans to leverage Kimberly-Clark's distribution and digital capabilities to accelerate Kenvue's growth while navigating challenges like Tylenol-related litigation and rising raw material costs.

Kimberly-Clark completes acquisition of Kenvue, creating global consumer health and wellness leader

https://chaindrugreview.com/kimberly-clark-completes-acquisition-of-kenvue-creating-global-consumer-health-and-wellness-leader/
Kimberly-Clark Corp. has completed its acquisition of Kenvue, merging two consumer product leaders to form a global health and wellness company. The combined entity now boasts 10 billion-dollar brands across personal care, family care, self-care, and consumer health, aiming to expand its reach in growing health and wellness markets. Kimberly-Clark expects to achieve approximately $2.1 billion in annual run-rate synergies from the acquisition, supported by a new operating structure across four geographic business segments.

Okta to Join S&P 500 Index, Replacing Kenvue Before Nov. 4 Open

https://finance.biggo.com/news/acfc22bc-9d36-4918-828d-2ba13d41999c
S&P Dow Jones Indices announced that Okta (OKTA) will be added to the S&P 500 Index on November 4, replacing Kenvue (KVUE) following its acquisition by Kimberly-Clark for $48.7 billion. Okta, specializing in identity and access management, has seen its shares surge by approximately 140% year-to-date, driven by increased cybersecurity demand, particularly due to AI agents. Analysts are largely bullish on Okta, with an average price target of $214.88.

Form 8K Kenvue Inc For: 2 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-kenvue-inc-for-2-november-93CH-4922592
This article announces that Kenvue Inc. filed a Form 8K on November 2, 2026. The Form 8K is a crucial document that public companies file with the U.S. Securities and Exchange Commission (SEC) to announce major events that shareholders should know about. No specific details about the content of the Form 8K are provided in this brief announcement.

Form S-8 KIMBERLY CLARK CORP

https://www.streetinsider.com/SEC+Filings/Form+S-8+KIMBERLY+CLARK+CORP/27271074.html
Kimberly-Clark Corporation has filed a Form S-8 registration statement in connection with its acquisition of Kenvue Inc. The filing details the conversion of Kenvue equity awards into Kimberly-Clark common stock awards for both continuing and former Kenvue employees and directors. It also registers additional shares under Kimberly-Clark's 2021 Equity Participation Plan to accommodate the acquired share reserves from Kenvue.
Advertisement

Kenvue Terminates $4 Billion Revolving Credit Facility After Merger Close

https://www.tradingview.com/news/tradingview:edc443b6fa08d:0-kenvue-terminates-4-billion-revolving-credit-facility-after-merger-close/
Kenvue terminated its five-year, $4.0 billion senior unsecured revolving credit facility with JPMorgan Chase Bank on November 2, 2026, coinciding with the close of its merger. The company repaid all outstanding obligations, with no borrowings reported at closing, and the facility was terminated ahead of schedule. This action was officially documented in an SEC filing.

Form 8-K Kenvue Inc. For: Nov 01

https://www.streetinsider.com/SEC+Filings/Form+8-K+Kenvue+Inc.+For%3A+Nov+01/27271056.html
This Form 8-K filing details the completion of the merger between Kenvue Inc. and Kimberly-Clark Corporation, where Kenvue became a wholly-owned subsidiary of K-C. It outlines the terms of the acquisition, including the merger consideration for Kenvue common stock shareholders and the conversion of equity awards. The report also covers the termination of Kenvue's material agreements, the delisting of Kenvue common stock from the NYSE, and changes to the company's directors and officers.

Kimberly-Clark grants CEO Michael Hsu $6.6 million in options after Kenvue deal

https://www.tradingview.com/news/tradingview:0be1cc5baac68:0-kimberly-clark-grants-ceo-michael-hsu-6-6-million-in-options-after-kenvue-deal/
Kimberly-Clark awarded CEO Michael Hsu $6.6 million in premium-priced stock options and granted similar awards to two other executives, Nelson Urdaneta and Jeffrey Melucci, for their leadership in completing the Kenvue acquisition. Additionally, the company appointed three former Kenvue directors to its board, filling vacancies created by three resignations, to further incentivize integration and synergy efforts. These stock options vest in full on December 1, 2029, contingent on continued employment.

CNH Industrial N.V. (CNH) Stock forecasts

https://sg.finance.yahoo.com/research/reports/ARGUS_6359_QuantitativeReport_1793145600000/
Argus has lowered its target price for CNH Industrial N.V. (CNH) to $11.00 from its current price of $11.76. CNH Industrial is recognized as the world's second-largest manufacturer of agricultural machinery, accounting for 82% of its industrial net sales, and is also a significant producer of construction equipment, making up 18% of its industrial net sales. The report, dated October 28, 2026, focuses on the Industrials sector.

Kenvue | 10-Q: Q3 2026 Earnings Report

https://www.moomoo.com/news/notice/1002998164/quarterly-report
This article is the Q3 2026 Earnings Report for Kenvue, presented as a 10-Q filing. It provides financial details and operational insights for the third quarter of 2026.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement